Status:
RECRUITING
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
Lead Sponsor:
The Cleveland Clinic
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Neuromuscular Blocks
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neost...
Detailed Description
The investigators propose a single-center, assessor-blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neost...
Eligibility Criteria
Inclusion
- ≥18 years old
- American Society of Anesthesiologist physical status 3-4
- Scheduled for outpatient endoscopic retrograde cholangiopancreatography
Exclusion
- Difficult Airway
- Neuromuscular Disorders (eg: ALS, Botulism, Myasthenia Gravis, Lambert-eaton syndrome)
- End stage renal disease requiring dialysis
- Pregnancy or breast-feeding
- Allergy to Fentanyl
- Allergy to Neuromuscular blocking drugs (eg: rocuronium)
- Allergy to Neuromuscular reversal drugs (eg: sugammadex or neostigmine)
- Allergy to glycopyrrolate
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06136585
Start Date
June 1 2024
End Date
December 31 2026
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Fairview Hospital
Cleveland, Ohio, United States, 44111